SF - I have also thought about this specific point at length. The way I see it is if there was an underlying issue with heart attacks and they were in the RVX208 dosed group then the trial would have a reasonable chance of being shut down by the DSMB. If however those heart attacks were being seen more in the placebo group then that would be in our favor, I think.

I look forward to BDAZ's comments about your question.

tada